MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ajo.2015.06.011

Медицинская библиотека · American journal of ophthalmology · 2015

Intravitreal anti-vascular endothelial growth factor treatment and the risk of thromboembolism.

Schlenker Matthew B, Thiruchelvam Deva, Redelmeier Donald A

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: To evaluate the subsequent risk of thromboembolic events in patients receiving intravitreal ranibizumab and bevacizumab for age-related macular degeneration or macular edema.

DESIGN

Population-based crossover analysis with self-matched historical control data.

METHODS

setting: Ontario, Canada, between April 1, 2006, and March 31, 2013.

STUDY POPULATION: Consecutive patients 65 and older who initiated intravitreal treatment (N = 57 919).

INTERVENTION: Intravitreal injection of ranibizumab or bevacizumab.

MAIN OUTCOME MEASURES: Emergency visits for thromboembolic events spanning 1-4 years before treatment were compared to 1 year after treatment. Also examined were other secondary events including hip fractures, congestive heart failure, angina, falls, depression, cholecystitis, and total emergencies, as well as a control group following cataract surgery.

RESULTS

A total of 57 919 patients were included who accounted for 1858 thromboembolic emergencies (48 per month) during the 3-year Baseline interval and 1077 thromboembolic emergencies (83 per month) during the 1-year Subsequent interval after initiating treatment. The absolute change in risk equaled an increase from 10.7 to 18.6 per 1000 patients annually after initiation of treatment (rate ratio 1.74; 95% confidence interval 1.58-1.92; P < .0001). The relative increase was particularly pronounced for ischemic stroke (rate ratio 2.18; 95% confidence interval 1.94-2.46; P < .0001). The observed increase exceeded trends due to aging, applied across patients with diverse characteristics, occurred with each medication (ranibizumab and bevacizumab), was not apparent for emergencies unrelated to thromboembolic events, and did not occur in a control group following cataract surgery.

CONCLUSIONS

Intravitreal anti-vascular endothelial growth factor medications ranibizumab and bevacizumab may contribute to systemic thromboembolic events in patients aged 65 years or older.

Для цитирования: Schlenker Matthew B, Thiruchelvam Deva, Redelmeier Donald A. Intravitreal anti-vascular endothelial growth factor treatment and the risk of thromboembolism.. American journal of ophthalmology. 2015. DOI: 10.1016/j.ajo.2015.06.011.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.